|
1
|
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J,
Wang B, Xiang H, Cheng Z, Xiong Y, et al: Clinical characteristics
of 138 hospitalized patients with 2019 novel coronavirus-infected
pneumonia in Wuhan, China. JAMA. 323:1061–1069. 2020.
|
|
2
|
Georgakopoulou VE, Makrodimitri S,
Triantafyllou M, Samara S, Voutsinas PM, Anastasopoulou A,
Papageorgiou CV, Spandidos DA, Gkoufa A, Papalexis P, et al:
Immature granulocytes: Innovative biomarker for SARS-CoV-2
infection. Mol Med Rep. 26:2172022.
|
|
3
|
Lempesis IG, Karlafti E, Papalexis P,
Fotakopoulos G, Tarantinos K, Lekakis V, Papadakos SP, Cholongitas
E and Georgakopoulou VE: COVID-19 and liver injury in individuals
with obesity. World J Gastroenterol. 29:908–916. 2023.
|
|
4
|
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He
JX, Liu L, Shan H, Lei CL, Hui DSC, et al: Clinical characteristics
of coronavirus disease 2019 in China. N Engl J Med. 382:1708–1720.
2020.
|
|
5
|
Gracia-Ramos AE, Jaquez-Quintana JO,
Contreras-Omana R and Auron M: Liver dysfunction and SARS-CoV-2
infection. World J Gastroenterol. 27:3951–3970. 2021.
|
|
6
|
Gkoufa A, Maneta E, Ntoumas GN,
Georgakopoulou VE, Mantelou A, Kokkoris S and Routsi C: Elderly
adults with COVID-19 admitted to intensive care unit: A narrative
review. World J Crit Care Med. 10:278–289. 2021.
|
|
7
|
Georgakopoulou VE, Gkoufa A, Garmpis N,
Makrodimitri S, Papageorgiou CV, Barlampa D, Garmpi A, Chiapoutakis
S, Sklapani P, Trakas N and Damaskos C: COVID-19 and acute
pancreatitis: A systematic review of case reports and case series.
Ann Saudi Med. 42:276–287. 2022.
|
|
8
|
Georgakopoulou VE, Lembessis P, Skarlis C,
Gkoufa A, Sipsas NV and Mavragani CP: Hematological abnormalities
in COVID-19 disease: Association with type I interferon pathway
activation and disease outcomes. Front Med (Lausanne).
9:8504722022.
|
|
9
|
Madjid M, Safavi-Naeini P, Solomon SD and
Vardeny O: Potential effects of coronaviruses on the cardiovascular
system: A review. JAMA Cardiol. 5:831–840. 2020.
|
|
10
|
Lempesis IG and Georgakopoulou VE:
Implications of obesity and adiposopathy on respiratory infections;
focus on emerging challenges. World J Clin Cases. 11:2925–2933.
2023.
|
|
11
|
Lempesis IG and Georgakopoulou VE:
Physiopathological mechanisms related to inflammation in obesity
and type 2 diabetes mellitus. World J Exp Med. 13:7–16. 2023.
|
|
12
|
Georgakopoulou VE, Bali T, Adamantou M,
Asimakopoulou S, Makrodimitri S, Samara S, Triantafyllou M,
Voutsinas PM, Eliadi I, Karamanakos G, et al: Acute hepatitis and
liver injury in hospitalized patients with COVID-19 infection. Exp
Ther Med. 24:6912022.
|
|
13
|
Mathioudakis N, Zachiotis M, Papadakos S,
Triantafyllou M, Karapanou A, Samara S, Karamanakos G, Spandidos
DA, Papalexis P, Damaskos C, et al: Onodera's prognostic
nutritional index: Comparison of its role in the severity and
outcomes of patients with COVID-19 during the periods of alpha,
delta and omicron variant predominance. Exp Ther Med.
24:6752022.
|
|
14
|
Cholongitas E, Bali T, Georgakopoulou VE,
Kamiliou A, Vergos I, Makrodimitri S, Samara S, Triantafylou M,
Basoulis D, Eliadi I, et al: Comparison of liver function test- and
inflammation-based prognostic scores for coronavirus disease 2019:
A single center study. Eur J Gastroenterol Hepatol. 34:1165–1171.
2022.
|
|
15
|
Georgakopoulou VE, Gkoufa A, Damaskos C,
Papalexis P, Pierrakou A, Makrodimitri S, Sypsa G, Apostolou A,
Asimakopoulou S, Chlapoutakis S, et al: COVID-19-associated acute
appendicitis in adults. A report of five cases and a review of the
literature. Exp Ther Med. 24:4822022.
|
|
16
|
Cholongitas E, Bali T, Georgakopoulou VE,
Giannakodimos A, Gyftopoulos A, Georgilaki V, Gerogiannis D,
Basoulis D, Eliadi I, Karamanakos G, et al: Prevalence of abnormal
liver biochemistry and its impact on COVID-19 patients' outcomes: A
single-center Greek study. Ann Gastroenterol. 35:290–296. 2022.
|
|
17
|
Loh D and Reiter RJ: Melatonin: Regulation
of viral phase separation and epitranscriptomics in post-acute
sequelae of COVID-19. Int J Mol Sci. 23:81222022.
|
|
18
|
Davis HE, McCorkell L, Vogel JM and Topol
EJ: Long COVID: Major findings, mechanisms and recommendations. Nat
Rev Microbiol. 21:133–146. 2023.
|
|
19
|
Mehandru S and Merad M: Pathological
sequelae of long-haul COVID. Nat Immunol. 23:194–202. 2022.
|
|
20
|
Vehar S, Boushra M, Ntiamoah P and Biehl
M: Post-acute sequelae of SARS-CoV-2 infection: Caring for the
'long-haulers'. Cleve Clin J Med. 88:267–272. 2021.
|
|
21
|
Bali T, Georgakopoulou VE, Kamiliou A,
Vergos I, Adamantou M, Vlachos S, Ermidis G, Sipsas NV, Samarkos M
and Cholongitas E: Abnormal liver function tests and coronavirus
disease 2019: A close relationship. J Viral Hepat. 30:79–80.
2023.
|
|
22
|
Guarnieri JW, Dybas JM, Fazelinia H, Kim
MS, Frere J, Zhang Y, Soto Albrecht Y, Murdock DG, Angelin A, Singh
LN, et al: Core mitochondrial genes are down-regulated during
SARS-CoV-2 infection of rodent and human hosts. Sci Transl Med.
15:eabq15332023.
|
|
23
|
Reiter RJ, Tan DX and Galano A: Melatonin:
Exceeding expectations. Physiology (Bethesda). 29:325–333.
2014.
|
|
24
|
Reiter RJ, Sharma R, Rosales-Corral S, de
Campos Zuccari DAP and de Almeida Chuffa LG: Melatonin: A
mitochondrial resident with a diverse skill set. Life Sci.
301:1206122022.
|
|
25
|
Reiter RJ, Sharma R, Tan DX, Neel RL,
Simko F, Manucha W, Rosales-Corral S and Cardinali DP: Melatonin
use for SARS-CoV-2 infection: Time to diversify the treatment
portfolio. J Med Virol. 94:2928–2930. 2022.
|
|
26
|
Romero A, Ramos E, López-Muñoz F,
Gil-Martín E, Escames G and Reiter RJ: Coronavirus disease 2019
(COVID-19) and its neuroinvasive capacity: Is it time for
melatonin? Cell Mol Neurobiol. 42:489–500. 2022.
|
|
27
|
Reiter RJ, Sharma R, Simko F,
Dominguez-Rodriguez A, Tesarik J, Neel RL, Slominski AT,
Kleszczynski K, Martin-Gimenez VM, Manucha W and Cardinali DP:
Melatonin: Highlighting its use as a potential treatment for
SARS-CoV-2 infection. Cell Mol Life Sci. 79:1432022.
|
|
28
|
Mouffak S, Shubbar Q, Saleh E and El-Awady
R: Recent advances in management of COVID-19: A review. Biomed
Pharmacother. 143:1121072021.
|
|
29
|
Wichniak A, Kania A, Siemiński M and
Cubała WJ: Melatonin as a potential adjuvant treatment for COVID-19
beyond sleep disorders. Int J Mol Sci. 22:86232021.
|
|
30
|
Ramos E, López-Muñoz F, Gil-Martín E, Egea
J, Álvarez-Merz I, Painuli S, Semwal P, Martins N, Hernández-Guijo
JM and Romero A: The coronavirus disease 2019 (COVID-19): key
emphasis on melatonin safety and therapeutic efficacy. Antioxidants
(Basel). 10:11522021.
|
|
31
|
Boga JA, Coto-Montes A, Rosales-Corral SA,
Tan DX and Reiter RJ: Beneficial actions of melatonin in the
management of viral infections: A new use for this 'molecular
handyman'? Rev Med Virol. 22:323–338. 2012.
|
|
32
|
Juybari KB, Pourhanifeh MH, Hosseinzadeh
A, Hemati K and Mehrzadi S: Melatonin potentials against viral
infections including COVID-19: Current evidence and new findings.
Virus Res. 287:1981082020.
|
|
33
|
Georgakopoulou VE, Gkoufa A, Makrodimitri
S, Basoulis D, Tsakanikas A, Karamanakos G, Mastrogianni E,
Voutsinas PM, Spandidos DA, Papageorgiou CV, et al: Early 3-day
course of remdesivir for the prevention of the progression to
severe COVID-19 in the elderly: A single-centre, real-life cohort
study. Exp Ther Med. 26:4622023.
|
|
34
|
Basoulis D, Tsakanikas A, Gkoufa A,
Bitsani A, Karamanakos G, Mastrogianni E, Georgakopoulou VE,
Makrodimitri S, Voutsinas PM, Lamprou P, et al: Effectiveness of
oral nirmatrelvir/ritonavir vs intravenous three-day remdesivir in
preventing progression to severe COVID-19: A single-center,
prospective, comparative, real-life study. Viruses.
15:15152023.
|
|
35
|
Papadopoulou A, Karavalakis G,
Papadopoulou E, Xochelli A, Bousiou Z, Vogiatzoglou A, Papayanni
PG, Georgakopoulou A, Giannaki M, Stavridou F, et al:
SARS-CoV-2-specific T cell therapy for severe COVID-19: a
randomized phase 1/2 trial. Nat Med. 29:2019–2029. 2023.
|
|
36
|
Karlafti E, Paramythiotis D, Pantazi K,
Georgakopoulou VE, Kaiafa G, Papalexis P, Protopapas AA, Ztriva E,
Fyntanidou V and Savopoulos C: Drug-induced liver injury in
hospitalized patients during SARS-CoV-2 infection. Medicina
(Kaunas). 58:18482022.
|
|
37
|
Georgakopoulou VE, Basoulis D, Voutsinas
PM, Makrodimitri S, Samara S, Triantafyllou M, Eliadi I,
Karamanakos G, Papageorgiou CV, Anastasopoulou A, et al: Factors
predicting poor outcomes of patients treated with tocilizumab for
COVID-19-associated pneumonia: A retrospective study. Exp Ther Med.
24:7242022.
|
|
38
|
Gkoufa A, Saridaki M, Georgakopoulou VE,
Spandidos DA and Cholongitas E: COVID-19 vaccination in liver
transplant recipients (Review). Exp Ther Med. 25:2912023.
|
|
39
|
Elrashdy F, Tambuwala MM, Hassan SS, Adadi
P, Seyran M, Abd El-Aziz TM, Rezaei N, Lal A, Aljabali AAA,
Kandimalla R, et al: Autoimmunity roots of the thrombotic events
after COVID-19 vaccination. Autoimmun Rev. 20:1029412021.
|
|
40
|
Taskou C, Sarantaki A, Beloukas A,
Georgakopoulou VE, Daskalakis G, Papalexis P and Lykeridou A:
Knowledge and attitudes of healthcare professionals regarding
perinatal influenza vaccination during the COVID-19 pandemic.
Vaccines (Basel). 11:1682023.
|
|
41
|
Goeser S, Ruble J and Chandler L:
Melatonin: Historical and clinical perspectives. J Pharmaceut Care
Pain Symptom Contr. 5:37–49. 1997.
|
|
42
|
Beyer CE, Steketee JD and Saphier D:
Antioxidant properties of melatonin-an emerging mystery. Biochem
Pharmacol. 56:1265–1272. 1998.
|
|
43
|
Ahmad SB, Ali A, Bilal M, Rashid SM, Wani
AB, Bhat RR and Rehman MU: Melatonin and health: Insights of
melatonin action, biological functions, and associated disorders.
Cell Mol Neurobiol. 43:2437–2458. 2023.
|
|
44
|
Hardeland R, Balzer I, Poeggeler B,
Fuhrberg B, Uría H, Behrmann G, Wolf R, Meyer TJ and Reiter RJ: On
the primary functions of melatonin in evolution: Mediation of
photoperiodic signals in a unicell, photooxidation, and scavenging
of free radicals. J Pineal Res. 18:104–111. 1995.
|
|
45
|
Cipolla-Neto J and Amaral FGD: Melatonin
as a hormone: New physiological and clinical insights. Endocr Rev.
39:990–1028. 2018.
|
|
46
|
Manchester LC, Coto-Montes A, Boga JA,
Andersen LP, Zhou Z, Galano A, Vriend J, Tan DX and Reiter RJ:
Melatonin: An ancient molecule that makes oxygen metabolically
tolerable. J Pineal Res. 59:403–419. 2015.
|
|
47
|
Hardeland R, Reiter R, Poeggeler B and Tan
DX: The significance of the metabolism of the neurohormone
melatonin: Antioxidative protection and formation of bioactive
substances. Neurosci Biobehav Rev. 17:347–357. 1993.
|
|
48
|
Reiter RJ: Pineal melatonin: Cell biology
of its synthesis and of its physiological interactions. Endocr Rev.
12:151–180. 1991.
|
|
49
|
Hosseinzadeh A, Bagherifard A, Koosha F,
Amiri S, Karimi-Behnagh A, Reiter RJ and Mehrzadi S: Melatonin
effect on platelets and coagulation: Implications for a
prophylactic indication in COVID-19. Life Sci. 307:1208662022.
|
|
50
|
Tan DX, Hardeland R, Manchester LC,
Paredes SD, Korkmaz A, Sainz RM, Mayo JC, Fuentes-Broto L and
Reiter RJ: The changing biological roles of melatonin during
evolution: From an antioxidant to signals of darkness, sexual
selection and fitness. Biol Rev Camb Philos Soc. 85:607–623.
2010.
|
|
51
|
Andersen LPH, Gögenur I, Rosenberg J and
Reiter RJ: Pharmacokinetics of melatonin: The missing link in
clinical efficacy? Clin Pharmacokinet. 55:1027–1030. 2016.
|
|
52
|
Reiter RJ, Tan DX and Korkmaz A: The
circadian melatonin rhythm and its modulation: Possible impact on
hypertension. J Hypertens Suppl. 27:S17–S20. 2009.
|
|
53
|
Vriend J and Reiter RJ: Melatonin feedback
on clock genes: A theory involving the proteasome. J Pineal Res.
58:1–11. 2015.
|
|
54
|
Erren TC and Reiter RJ: Melatonin: A
universal time messenger. Neuro Endocrinol Lett. 36:187–192.
2015.
|
|
55
|
Mehrzadi S, Karimi MY, Fatemi A, Reiter RJ
and Hosseinzadeh A: SARS-CoV-2 and other coronaviruses negatively
influence mitochondrial quality control: Beneficial effects of
melatonin. Pharmacol Ther. 224:1078252021.
|
|
56
|
Mauriz JL, Collado PS, Veneroso C, Reiter
RJ and González-Gallego J: A review of the molecular aspects of
melatonin's anti-inflammatory actions: Recent insights and new
perspectives. J Pineal Res. 54:1–14. 2013.
|
|
57
|
Slominski RM, Reiter RJ,
Schlabritz-Loutsevitch N, Ostrom RS and Slominski AT: Melatonin
membrane receptors in peripheral tissues: Distribution and
functions. Mol Cell Endocrinol. 351:152–166. 2012.
|
|
58
|
Gurunathan S, Kang MH, Choi Y, Reiter RJ
and Kim JH: Melatonin: A potential therapeutic agent against
COVID-19. Melatonin Res. 4:30–69. 2021.
|
|
59
|
Naskar A, Prabhakar V, Singh R, Dutta D
and Mohanakumar KP: Melatonin enhances L-DOPA therapeutic effects,
helps to reduce its dose, and protects dopaminergic neurons in
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism
in mice. J Pineal Res. 58:262–274. 2015.
|
|
60
|
Reiter RJ, Mayo JC, Tan DX, Sainz RM,
Alatorre-Jimenez M and Qin L: Melatonin as an antioxidant: Under
promises but over delivers. J Pineal Res. 61:253–278. 2016.
|
|
61
|
Ramos E, Patiño P, Reiter RJ, Gil-Martín
E, Marco-Contelles J, Parada E, de Los Rios C, Romero A and Egea J:
Ischemic brain injury: New insights on the protective role of
melatonin. Free Radic Biol Med. 104:32–53. 2017.
|
|
62
|
Sanchez-Barcelo EJ, Rueda N, Mediavilla
MD, Martinez-Cue C and Reiter RJ: Clinical uses of melatonin in
neurological diseases and mental and behavioural disorders. Curr
Med Chem. 24:3851–3878. 2017.
|
|
63
|
Ali T, Rahman SU, Hao Q, Li W, Liu Z, Ali
Shah F, Murtaza I, Zhang Z, Yang X, Liu G and Li S: Melatonin
prevents neuroinflammation and relieves depression by attenuating
autophagy impairment through FOXO3a regulation. J Pineal Res.
69:e126672020.
|
|
64
|
Vriend J and Reiter RJ: Melatonin as a
proteasome inhibitor. Is there any clinical evidence? Life Sci.
115:8–14. 2014.
|
|
65
|
Mayo JC, Sainz RM, González Menéndez P,
Cepas V, Tan DX and Reiter RJ: Melatonin and sirtuins: A 'not-so
unexpected' relationship. J Pineal Res. 62:e123912017.
|
|
66
|
Gurunathan S, Qasim M, Kang MH and Kim JH:
Role and therapeutic potential of melatonin in various type of
cancers. Onco Targets Ther. 14:2019–2052. 2021.
|
|
67
|
Pourhanifeh MH, Mehrzadi S, Kamali M and
Hosseinzadeh A: Melatonin and gastrointestinal cancers: Current
evidence based on underlying signaling pathways. Eur J Pharmacol.
886:1734712020.
|
|
68
|
Reiter RJ, Rosales-Corral SA, Tan DX,
Acuna-Castroviejo D, Qin L, Yang SF and Xu K: Melatonin, a full
service anti-cancer agent: inhibition of initiation, progression
and metastasis. Int J Mol Sci. 18:8432017.
|
|
69
|
Reiter RJ, Tan DX, Paredes SD and
Fuentes-Broto L: Beneficial effects of melatonin in cardiovascular
disease. Ann Med. 42:276–285. 2010.
|
|
70
|
Galano A, Tan DX and Reiter RJ: Melatonin:
A versatile protector against oxidative DNA damage. Molecules.
23:5302018.
|
|
71
|
Simko F, Baka T, Paulis L and Reiter RJ:
Elevated heart rate and nondipping heart rate as potential targets
for melatonin: A review. J Pineal Res. 61:127–137. 2016.
|
|
72
|
Reiter RJ, Tan DX, Kim SJ and Qi W:
Melatonin as a pharmacological agent against oxidative damage to
lipids and DNA. Proc West Pharmacol Soc. 41:229–236. 1998.
|
|
73
|
Reiter RJ, Tan DX, Rosales-Corral S and
Manchester LC: The universal nature, unequal distribution and
antioxidant functions of melatonin and its derivatives. Mini Rev
Med Chem. 13:373–384. 2013.
|
|
74
|
García JJ, López-Pingarrón L,
Almeida-Souza P, Tres A, Escudero P, García-Gil FA, Tan DX, Reiter
RJ, Ramírez JM and Bernal-Pérez M: Protective effects of melatonin
in reducing oxidative stress and in preserving the fluidity of
biological membranes: A review. J Pineal Res. 56:225–237. 2014.
|
|
75
|
Tan DX, Korkmaz A, Reiter RJ and
Manchester LC: Ebola virus disease: Potential use of melatonin as a
treatment. J Pineal Res. 57:381–384. 2014.
|
|
76
|
Reiter RJ, Ma Q and Sharma R: Treatment of
Ebola and other infectious diseases: Melatonin 'goes viral'.
Melatonin Res. 3:43–57. 2020.
|
|
77
|
Reiter RJ, Sharma R, Ma Q, Liu C, Manucha
W, González P and Dominguez-Rodriguez A: Metabolic plasticity of
activated immune cells: Advantages for suppression of COVID-19
disease by melatonin. Melatonin Res. 3:362–379. 2020.
|
|
78
|
Reiter RJ, Sharma R, Ma Q,
Dominquez-Rodriguez A, Marik PE and Abreu-Gonzalez P: Melatonin
inhibits COVID-19-induced cytokine storm by reversing aerobic
glycolysis in immune cells: A mechanistic analysis. Med Drug
Discov. 6:1000442020.
|
|
79
|
Sarkar S, Chattopadhyay A and
Bandyopadhyay D: Multiple strategies of melatonin protecting
against cardiovascular injury related to inflammation: A
comprehensive overview. Melatonin Res. 4:1–29. 2021.
|
|
80
|
Esposito E and Cuzzocrea S:
Antiinflammatory activity of melatonin in central nervous system.
Curr Neuropharmacol. 8:228–242. 2010.
|
|
81
|
Hardeland R, Cardinali DP, Brown GM and
Pandi-Perumal SR: Melatonin and brain inflammaging. Prog Neurobiol.
127-128:46–63. 2015.
|
|
82
|
Farez MF, Mascanfroni ID, Méndez-Huergo
SP, Yeste A, Murugaiyan G, Garo LP, Balbuena Aguirre ME, Patel B,
Ysrraelit MC, Zhu C, et al: Melatonin contributes to the
seasonality of multiple sclerosis relapses. Cell. 162:1338–1352.
2015.
|
|
83
|
Dominguez-Rodriguez A, Abreu-Gonzalez P,
Marik PE and Reiter RJ: Melatonin, cardiovascular disease and
COVID-19: A potential therapeutic strategy? Melatonin Res.
3:318–321. 2020.
|
|
84
|
Ozdemir G, Ergün Y, Bakariş S, Kılınç M,
Durdu H and Ganiyusufoğlu E: Melatonin prevents retinal oxidative
stress and vascular changes in diabetic rats. Eye (Lond).
28:1020–1027. 2014.
|
|
85
|
Gheban BA, Rosca IA and Crisan M: The
morphological and functional characteristics of the pineal gland.
Med Pharm Rep. 92:226–234. 2019.
|
|
86
|
Cipolla-Neto J, Amaral F, Afeche SC, Tan
DX and Reiter RJ: Melatonin, energy metabolism, and obesity: A
review. J Pineal Res. 56:371–381. 2014.
|
|
87
|
Lempesis IG, Hoebers N, Essers Y, Jocken
JWE, Dineen R, Blaak EE, Manolopoulos KN and Goossens GH: Distinct
inflammatory signatures of upper and lower body adipose tissue and
adipocytes in women with normal weight or obesity. Front Endocrinol
(Lausanne). 14:12057992023.
|
|
88
|
Lempesis IG, Varrias D, Sagris M, Attaran
RR, Altin ES, Bakoyiannis C, Palaiodimos L, Dalamaga M and
Kokkinidis DG: Obesity and peripheral artery disease: Current
evidence and controversies. Curr Obes Rep. 12:264–279. 2023.
|
|
89
|
Lempesis IG, Apple SJ, Duarte G,
Palaiodimos L, Kalaitzopoulos DR, Dalamaga M and Kokkinidis DG:
Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary
syndrome. Diabetes Metab Res Rev. 39:e36822023.
|
|
90
|
Lempesis IG, Tsilingiris D, Liu J and
Dalamaga M: Of mice and men: Considerations on adipose tissue
physiology in animal models of obesity and human studies. Metabol
Open. 15:1002082022.
|
|
91
|
Simko F, Hrenak J, Dominguez-Rodriguez A
and Reiter RJ: Melatonin as a putative protection against
myocardial injury in COVID-19 infection. Expert Rev Clin Pharmacol.
13:921–924. 2020.
|
|
92
|
Mirza-Aghazadeh-Attari M, Reiter RJ,
Rikhtegar R, Jalili J, Hajalioghli P, Mihanfar A, Majidinia M and
Yousefi B: Melatonin: An atypical hormone with major functions in
the regulation of angiogenesis. IUBMB Life. 72:1560–1584. 2020.
|
|
93
|
Melhuish Beaupre LM, Brown GM, Gonçalves
VF and Kennedy JL: Melatonin's neuroprotective role in mitochondria
and its potential as a biomarker in aging, cognition and
psychiatric disorders. Transl Psychiatry. 11:3392021.
|
|
94
|
Reiter RJ, Rosales-Corral S, Tan DX, Jou
MJ, Galano A and Xu B: Melatonin as a mitochondria-targeted
antioxidant: One of evolution's best ideas. Cell Mol Life Sci.
74:3863–3881. 2017.
|
|
95
|
Reiter RJ, Ma Q and Sharma R: Melatonin in
mitochondria: Mitigating clear and present dangers. Physiology
(Bethesda). 35:86–95. 2020.
|
|
96
|
Wakatsuki A, Okatani Y, Shinohara K,
Ikenoue N, Kaneda C and Fukaya T: Melatonin protects fetal rat
brain against oxidative mitochondrial damage. J Pineal Res.
30:22–28. 2001.
|
|
97
|
Reiter RJ, Tan DX, Rosales-Corral S,
Galano A, Jou MJ and Acuna-Castroviejo D: Melatonin mitigates
mitochondrial meltdown: Interactions with SIRT3. Int J Mol Sci.
19:24392018.
|
|
98
|
Han L, Wang H, Li L, Li X, Ge J, Reiter RJ
and Wang Q: Melatonin protects against maternal obesity-associated
oxidative stress and meiotic defects in oocytes via the
SIRT3-SOD2-dependent pathway. J Pineal Res. 63:e124312017.
|
|
99
|
Mar tín M, Macías M, Escames G, León J and
Acuña-Castroviejo D: Melatonin but not vitamins C and E maintains
glutathione homeostasis in t-butyl hydroperoxide-induced
mitochondrial oxidative stress. FASEB J. 14:1677–1679. 2000.
|
|
100
|
Venegas C, García JA, Escames G, Ortiz F,
López A, Doerrier C, García-Corzo L, López LC, Reiter RJ and
Acuña-Castroviejo D: Extrapineal melatonin: Analysis of its
subcellular distribution and daily fluctuations. J Pineal Res.
52:217–227. 2012.
|
|
101
|
Suofu Y, Li W, Jean-Alphonse FG, Jia J,
Khattar NK, Li J, Baranov SV, Leronni D, Mihalik AC, He Y, et al:
Dual role of mitochondria in producing melatonin and driving GPCR
signaling to block cytochrome c release. Proc Natl Acad Sci USA.
114:E7997–E8006. 2017.
|
|
102
|
He C, Wang J, Zhang Z, Yang M, Li Y, Tian
X, Ma T, Tao J, Zhu K, Song Y, et al: Mitochondria synthesize
melatonin to ameliorate its function and improve mice oocyte's
quality under in vitro conditions. Int J Mol Sci. 17:9392016.
|
|
103
|
Tan DX and Reiter RJ: Mitochondria: The
birth place, battle ground and the site of melatonin metabolism in
cells. Melatonin Res. 2:44–66. 2019.
|
|
104
|
Chumboatong W, Thummayot S, Govitrapong P,
Tocharus C, Jittiwat J and Tocharus J: Neuroprotection of
agomelatine against cerebral ischemia/reperfusion injury through an
antiapoptotic pathway in rat. Neurochem Int. 102:114–122. 2017.
|
|
105
|
de Vries HE, Witte M, Hondius D,
Rozemuller AJ, Drukarch B, Hoozemans J and van Horssen J:
Nrf2-induced antioxidant protection: A promising target to
counteract ROS-mediated damage in neurodegenerative disease? Free
Radic Biol Med. 45:1375–1383. 2008.
|
|
106
|
Martin M, Macias M, Escames G, Reiter RJ,
Agapito MT, Ortiz GG and Acuña-Castroviejo D: Melatonin-induced
increased activity of the respiratory chain complexes I and IV can
prevent mitochondrial damage induced by ruthenium red in vivo. J
Pineal Res. 28:242–248. 2000.
|
|
107
|
Sheleme T, Bekele F and Ayela T: Clinical
presentation of patients infected with coronavirus disease 19: A
systematic review. Infect Dis (Auckl). 13:11786337209520762020.
|
|
108
|
Lempesis IG, Georgakopoulou VE, Papalexis
P, Chrousos GP and Spandidos DA: Role of stress in the pathogenesis
of cancer (Review). Int J Oncol. 63:1242023.
|
|
109
|
Georgakopoulou VE, Gkoufa A, Bougea A,
Basoulis D, Tsakanikas A, Makrodimitri S, Karamanakos G, Spandidos
DA, Angelopoulou E and Sipsas NV: Characteristics and outcomes of
elderly patients with Parkinson's disease hospitalized due to
COVID-19-associated pneumonia. Med Int (Lond). 3:342023.
|
|
110
|
Bourgonje AR, Abdulle AE, Timens W,
Hillebrands JL, Navis GJ, Gordijn SJ, Bolling MC, Dijkstra G, Voors
AA, Osterhaus AD, et al: Angiotensin-converting enzyme 2 (ACE2),
SARS-CoV-2 and the pathophysiology of coronavirus disease 2019
(COVID-19). J Pathol. 251:228–248. 2020.
|
|
111
|
Ozkurt Z and Çınar Tanrıverdi E: COVID-19:
Gastrointestinal manifestations, liver injury and recommendations.
World J Clin Cases. 10:1140–1163. 2022.
|
|
112
|
Zhang Q, Xiang R, Huo S, Zhou Y, Jiang S,
Wang Q and Yu F: Molecular mechanism of interaction between
SARS-CoV-2 and host cells and interventional therapy. Signal
Transduct Target Ther. 6:2332021.
|
|
113
|
Georgakopoulou VE, Gkoufa A, Tsakanikas A,
Makrodimitri S, Karamanakos G, Basoulis D, Voutsinas PM, Eliadi I,
Bougea A, Spandidos DA, et al: Predictors of COVID-19-associated
mortality among hospitalized elderly patients with dementia. Exp
Ther Med. 26:3952023.
|
|
114
|
Thakur V, Ratho RK, Kumar P, Bhatia SK,
Bora I, Mohi GK, Saxena SK, Devi M, Yadav D and Mehariya S:
Multi-organ involvement in COVID-19: Beyond pulmonary
manifestations. J Clin Med. 10:4462021.
|
|
115
|
Martín Giménez VM, de las Heras N, Ferder
L, Lahera V, Reiter RJ and Manucha W: Potential Effects of
melatonin and micronutrients on mitochondrial dysfunction during a
cytokine storm typical of oxidative/inflammatory diseases.
Diseases. 9:302021.
|
|
116
|
Bougea A, Georgakopoulou VE, Palkopoulou
M, Efthymiopoulou E, Angelopoulou E, Spandidos DA and Zikos P:
New-onset non-motor symptoms in patients with Parkinson's disease
and post-COVID-19 syndrome: A prospective cross-sectional study.
Med Int (Lond). 3:232023.
|
|
117
|
Ahmad I and Rathore FA: Neurological
manifestations and complications of COVID-19: A literature review.
J Clin Neurosci. 77:8–12. 2020.
|
|
118
|
Long B, Brady WJ, Koyfman A and Gottlieb
M: Cardiovascular complications in COVID-19. Am J Emerg Med.
38:1504–1507. 2020.
|
|
119
|
Legrand M, Bell S, Forni L, Joannidis M,
Koyner JL, Liu K and Cantaluppi V: Pathophysiology of
COVID-19-associated acute kidney injury. Nat Rev Nephrol.
17:751–764. 2021.
|
|
120
|
Thaweethai T, Jolley SE, Karlson EW,
Levitan EB, Levy B, McComsey GA, McCorkell L, Nadkarni GN,
Parthasarathy S, Singh U, et al: Development of a definition of
postacute sequelae of SARS-CoV-2 infection. JAMA. 329:1934–1946.
2023.
|
|
121
|
Efstathiou V, Stefanou MI, Demetriou M,
Siafakas N, Makris M, Tsivgoulis G, Zoumpourlis V, Kympouropoulos
SP, Tsoporis JN, Spandidos DA, et al: Long COVID and
neuropsychiatric manifestations (Review). Exp Ther Med.
23:3632022.
|
|
122
|
Efstathiou V, Stefanou MI, Demetriou M,
Siafakas N, Katsantoni E, Makris M, Tsivgoulis G, Zoumpourlis V,
Kympouropoulos SP, Tsoporis JN, et al: New-onset neuropsychiatric
sequelae and 'long-COVID'syndrome (Review). Exp Ther Med.
24:7052022.
|
|
123
|
Daugherty SE, Guo Y, Heath K, Dasmariñas
MC, Jubilo KG, Samranvedhya J, Lipsitch M and Cohen K: Risk of
clinical sequelae after the acute phase of SARS-CoV-2 infection:
Retrospective cohort study. BMJ. 373:n10982021.
|
|
124
|
Huang L, Li X, Gu X, Zhang H, Ren L, Guo
L, Liu M, Wang Y, Cui D, Wang Y, et al: Health outcomes in people 2
years after surviving hospitalisation with COVID-19: A longitudinal
cohort study. Lancet Respir Med. 10:863–876. 2022.
|
|
125
|
Huang C, Huang L, Wang Y, Li X, Ren L, Gu
X, Kang L, Guo L, Liu M, Zhou X, et al: 6-Month consequences of
COVID-19 in patients discharged from hospital: A cohort study.
Lancet. 397:220–232. 2021.
|
|
126
|
E E, R F, Öi E, Im L, M L, S R, E W, C J,
M H and A M: Impaired diffusing capacity for carbon monoxide is
common in critically ill Covid-19 patients at four months
post-discharge. Respir Med. 182:1063942021.
|
|
127
|
Antonelli M, Pujol JC, Spector TD,
Ourselin S and Steves CJ: Risk of long COVID associated with delta
versus omicron variants of SARS-CoV-2. Lancet. 399:2263–2264.
2022.
|
|
128
|
Quaglia F, Salladini E, Carraro M,
Minervini G, Tosatto SCE and Le Mercier P: SARS-CoV-2 variants
preferentially emerge at intrinsically disordered protein sites
helping immune evasion. FEBS J. 289:4240–4250. 2022.
|
|
129
|
Lipsitch M, Krammer F, Regev-Yochay G,
Lustig Y and Balicer RD: SARS-CoV-2 breakthrough infections in
vaccinated individuals: Measurement, causes and impact. Nat Rev
Immunol. 22:57–65. 2022.
|
|
130
|
Hayes LD, Ingram J and Sculthorpe NF: More
than 100 persistent symptoms of SARS-CoV-2 (long COVID): A scoping
review. Front Med (Lausanne). 8:7503782021.
|
|
131
|
Davis HE, Assaf GS, McCorkell L, Wei H,
Low RJ, Re'em Y, Redfield S, Austin JP and Akrami A: Characterizing
long COVID in an international cohort: 7 Months of symptoms and
their impact. EClinicalMedicine. 38:1010192021.
|
|
132
|
Gaebler C, Wang Z, Lorenzi JCC, Muecksch
F, Finkin S, Tokuyama M, Cho A, Jankovic M, Schaefer-Babajew D,
Oliveira TY, et al: Evolution of antibody immunity to SARS-CoV-2.
Nature. 591:639–644. 2021.
|
|
133
|
Proal AD and VanElzakker MB: Long COVID or
post-acute sequelae of COVID-19 (PASC): An overview of biological
factors that may contribute to persistent symptoms. Front
Microbiol. 12:6981692021.
|
|
134
|
Kalkeri R, Goebel S and Sharma GD:
SARS-CoV-2 shedding from asymptomatic patients: Contribution of
potential extrapulmonary tissue reservoirs. Am J Trop Med Hyg.
103:18–21. 2020.
|
|
135
|
Zubchenko S, Kril I, Nadizhko O, Matsyura
O and Chopyak V: Herpesvirus infections and post-COVID-19
manifestations: A pilot observational study. Rheumatol Int.
42:1523–1530. 2022.
|
|
136
|
Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi
J, Li S, Hong S, Zhang R, Xie J, et al: Multiple early factors
anticipate post-acute COVID-19 sequelae. Cell. 185:881–895.e20.
2022.
|
|
137
|
Schreiner P, Harrer T, Scheibenbogen C,
Lamer S, Schlosser A, Naviaux RK and Prusty BK: Human herpesvirus-6
reactivation, mitochondrial fragmentation, and the coordination of
antiviral and metabolic phenotypes in myalgic
encephalomyelitis/chronic fatigue syndrome. Immunohorizons.
4:201–215. 2020.
|
|
138
|
Peluso MJ, Deeks SG, Mustapic M,
Kapogiannis D, Henrich TJ, Lu S, Goldberg SA, Hoh R, Chen JY,
Martinez EO, et al: SARS-CoV-2 and mitochondrial proteins in
neural-derived exosomes of COVID-19. Ann Neurol. 91:772–781.
2022.
|
|
139
|
Villaume WA: Marginal BH4 deficiencies,
iNOS, and self-perpetuating oxidative stress in post-acute sequelae
of Covid-19. Med Hypotheses. 163:1108422022.
|
|
140
|
Saleh J, Peyssonnaux C, Singh KK and Edeas
M: Mitochondria and microbiota dysfunction in COVID-19
pathogenesis. Mitochondrion. 54:1–7. 2020.
|
|
141
|
Singh KK, Chaubey G, Chen JY and
Suravajhala P: Decoding SARS-CoV-2 hijacking of host mitochondria
in COVID-19 pathogenesis. Am J Physiol Cell Physiol. 319:C258–C267.
2020.
|
|
142
|
Marchi S, Guilbaud E, Tait SWG, Yamazaki T
and Galluzzi L: Mitochondrial control of inflammation. Nat Rev
Immunol. 23:159–173. 2023.
|
|
143
|
West AP and Shadel GS: Mitochondrial DNA
in innate immune responses and inflammatory pathology. Nat Rev
Immunol. 17:363–375. 2017.
|
|
144
|
Wang P, Luo R, Zhang M, Wang Y, Song T,
Tao T, Li Z, Jin L, Zheng H, Chen W, et al: A cross-talk between
epithelium and endothelium mediates human alveolar-capillary injury
during SARS-CoV-2 infection. Cell Death Dis. 11:10422020.
|
|
145
|
Cortese M, Lee JY, Cerikan B, Neufeldt CJ,
Oorschot VMJ, Köhrer S, Hennies J, Schieber NL, Ronchi P, Mizzon G,
et al: Integrative imaging reveals SARS-CoV-2-induced reshaping of
subcellular morphologies. Cell Host Microbe. 28:853–866.e5.
2020.
|
|
146
|
Hui DS, I Azhar E, Madani TA, Ntoumi F,
Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C, et al:
The continuing 2019-nCoV epidemic threat of novel coronaviruses to
global health-the latest 2019 novel coronavirus outbreak in Wuhan,
China. Int J Infect Dis. 91:264–266. 2020.
|
|
147
|
Gordon DE, Hiatt J, Bouhaddou M, Rezelj
VV, Ulferts S, Braberg H, Jureka AS, Obernier K, Guo JZ, Batra J,
et al: Comparative host-coronavirus protein interaction networks
reveal pan-viral disease mechanisms. Science. 370:eabe94032020.
|
|
148
|
Gordon DE, Jang GM, Bouhaddou M, Xu J,
Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL, et
al: A SARS-CoV-2 protein interaction map reveals targets for drug
repurposing. Nature. 583:459–468. 2020.
|
|
149
|
Stukalov A, Girault V, Grass V, Karayel O,
Bergant V, Urban C, Haas DA, Huang Y, Oubraham L, Wang A, et al:
Multilevel proteomics reveals host perturbations by SARS-CoV-2 and
SARS-CoV. Nature. 594:246–252. 2021.
|
|
150
|
Li S, Ma F, Yokota T, Garcia G Jr, Palermo
A, Wang Y, Farrell C, Wang YC, Wu R, Zhou Z, et al: Metabolic
reprogramming and epigenetic changes of vital organs in
SARS-CoV-2-induced systemic toxicity. JCI insight.
6:e1450272021.
|
|
151
|
Bojkova D, Klann K, Koch B, Widera M,
Krause D, Ciesek S, Cinatl J and Münch C: Proteomics of
SARS-CoV-2-infected host cells reveals therapy targets. Nature.
583:469–472. 2020.
|
|
152
|
Miller B, Silverstein A, Flores M, Cao K,
Kumagai H, Mehta HH, Yen K, Kim SJ and Cohen P: Host mitochondrial
transcriptome response to SARS-CoV-2 in multiple cell models and
clinical samples. Sci Rep. 11:32021.
|
|
153
|
Medini H, Zirman A and Mishmar D: Immune
system cells from COVID-19 patients display compromised
mitochondrial-nuclear expression co-regulation and rewiring toward
glycolysis. iScience. 24:1034712021.
|
|
154
|
Codo AC, Davanzo GG, Monteiro LB, de Souza
GF, Muraro SP, Virgilio-da-Silva JV, Prodonoff JS, Carregari VC, de
Biagi Junior CAO, Crunfli F, et al: Elevated glucose levels favor
SARS-CoV-2 infection and monocyte response through a
HIF-1α/glycolysis-dependent axis. Cell Metab. 32:437–446.e5.
2020.
|
|
155
|
Tian M, Liu W, Li X, Zhao P, Shereen MA,
Zhu C, Huang S, Liu S, Yu X, Yue M, et al: HIF-1α promotes
SARS-CoV-2 infection and aggravates inflammatory responses to
COVID-19. Signal Transduct Target Ther. 6:3082021.
|
|
156
|
Tan DX and Reiter RJ: Mechanisms and
clinical evidence to support melatonin's use in severe COVID-19
patients to lower mortality. Life Sci. 294:1203682022.
|
|
157
|
Huang PY, Wu JY, Liu TH, Tsai YW, Chen PT,
Liao CT and Toh HS: The clinical efficacy of melatonin in the
treatment of patients with COVID-19: A systematic review and
meta-analysis of randomized controlled trials. Front Med
(Lausanne). 10:11712942023.
|
|
158
|
Fara A, Mitrev Z, Rosalia RA and Assas BM:
Cytokine storm and COVID-19: A chronicle of pro-inflammatory
cytokines. Open Biol. 10:2001602020.
|
|
159
|
Reiter RJ, Abreu-Gonzalez P, Marik PE and
Dominguez-Rodriguez A: Therapeutic algorithm for use of melatonin
in patients with COVID-19. Front Med (Lausanne). 7:2262020.
|
|
160
|
Tan DX, Manchester LC, Terron MP, Flores
LJ and Reiter RJ: One molecule, many derivatives: A never-ending
interaction of melatonin with reactive oxygen and nitrogen species?
J Pineal Res. 42:28–42. 2007.
|
|
161
|
Tan DX, Hardeland R, Manchester LC,
Poeggeler B, Lopez-Burillo S, Mayo JC, Sainz RM and Reiter RJ:
Mechanistic and comparative studies of melatonin and classic
antioxidants in terms of their interactions with the ABTS cation
radical. J Pineal Res. 34:249–259. 2003.
|
|
162
|
Rodriguez C, Mayo JC, Sainz RM, Antolín I,
Herrera F, Martín V and Reiter RJ: Regulation of antioxidant
enzymes: A significant role for melatonin. J Pineal Res. 36:1–9.
2004.
|
|
163
|
Cuzzocrea S, Zingarelli B, Costantino G
and Caputi AR: Protective effect of melatonin in a non-septic shock
model induced by zymosan in the rat. J Pineal Res. 25:24–33.
1998.
|
|
164
|
Cuzzocrea S, Zingarelli B, Gilad E, Hake
P, Salzman AL and Szabó C: Protective effect of melatonin in
carrageenan-induced models of local inflammation: Relationship to
its inhibitory effect on nitric oxide production and its
peroxynitrite scavenging activity. J Pineal Res. 23:106–116.
1997.
|
|
165
|
El-Sokkary GH, Omar HM, Hassanein AFMM,
Cuzzocrea S and Reiter RJ: Melatonin reduces oxidative damage and
increases survival of mice infected with Schistosoma mansoni. Free
Radic Biol Med. 32:319–332. 2002.
|
|
166
|
Costantino G, Cuzzocrea S, Mazzon E and
Caputi AP: Protective effects of melatonin in zymosan-activated
plasma-induced paw inflammation. Eur J Pharmacol. 363:57–63.
1998.
|
|
167
|
Kong J, Zhang Y, Liu S, Li H, Liu S, Wang
J, Qin X, Jiang X, Yang J, Zhang C and Zhang W: Melatonin
attenuates angiotensin II-induced abdominal aortic aneurysm through
the down-regulation of matrix metalloproteinases. Oncotarget.
8:14283–14293. 2017.
|
|
168
|
Zhang Y and Li X, Grailer JJ, Wang N, Wang
M, Yao J, Zhong R, Gao GF, Ward PA, Tan DX and Li X: Melatonin
alleviates acute lung injury through inhibiting the NLRP3
inflammasome. J Pineal Res. 60:405–414. 2016.
|
|
169
|
Kaivola J, Nyman TA and Matikainen S:
Inflammasomes and SARS-CoV-2 infection. Viruses. 13:25132021.
|
|
170
|
Kucia M, Ratajczak J, Bujko K, Adamiak M,
Ciechanowicz A, Chumak V, Brzezniakiewicz-Janus K and Ratajczak MZ:
An evidence that SARS-Cov-2/COVID-19 spike protein (SP) damages
hematopoietic stem/progenitor cells in the mechanism of pyroptosis
in Nlrp3 inflammasome-dependent manner. Leukemia. 35:3026–3029.
2021.
|
|
171
|
Davies DA, Adlimoghaddam A and Albensi BC:
The effect of COVID-19 on NF-κB and neurological manifestations of
disease. Mol Neurobiol. 58:4178–4187. 2021.
|
|
172
|
Manik M and Singh RK: Role of toll-like
receptors in modulation of cytokine storm signaling in
SARS-CoV-2-induced COVID-19. J Med Virol. 94:869–877. 2022.
|
|
173
|
Li HW, Ying P, Cai QQ, Yang ZH and Wu XL:
Exogenous melatonin alleviates hemorrhagic shock-induced hepatic
ischemic injury in rats by inhibiting the NF-κB/IκBα signaling
pathway. Mol Med Rep. 23:3412021.
|
|
174
|
Qin M, Liu Y, Sun M, Li X, Xu J, Zhang L
and Jiang H: Protective effects of melatonin on the white matter
damage of neonatal rats by regulating NLRP3 inflammasome activity.
Neuroreport. 32:739–747. 2021.
|
|
175
|
Cao S, Shrestha S, Li J, Yu X, Chen J, Yan
F, Ying G, Gu C, Wang L and Chen G: Melatonin-mediated mitophagy
protects against early brain injury after subarachnoid hemorrhage
through inhibition of NLRP3 inflammasome activation. Sci Rep.
7:24172017.
|
|
176
|
Tan DX and Hardeland R: Targeting host
defense system and rescuing compromised mitochondria to increase
tolerance against pathogens by melatonin may impact outcome of
deadly virus infection pertinent to COVID-19. Molecules.
25:44102020.
|
|
177
|
Sygitowicz G and Sitkiewicz D: Molecular
mechanisms of organ damage in sepsis: An overview. Braz J Infect
Dis. 24:552–560. 2020.
|
|
178
|
Luo J, Song J, Zhang H, Zhang F, Liu H, Li
L, Zhang Z, Chen L, Zhang M, Lin D, et al: Melatonin mediated
Foxp3-downregulation decreases cytokines production via the TLR2
and TLR4 pathways in H. pylori infected mice. Int Immunopharmacol.
64:116–122. 2018.
|
|
179
|
Xu X, Wang G, Ai L, Shi J, Zhang J and
Chen YX: Melatonin suppresses TLR9-triggered proinflammatory
cytokine production in macrophages by inhibiting ERK1/2 and AKT
activation. Sci Rep. 8:155792018.
|
|
180
|
Feng R, Adeniran SO, Huang F, Li Y, Ma M,
Zheng P and Zhang G: The ameliorative effect of melatonin on
LPS-induced Sertoli cells inflammatory and tight junctions damage
via suppression of the TLR4/MyD88/NF-κB signaling pathway in
newborn calf. Theriogenology. 179:103–116. 2022.
|
|
181
|
Tan DX and Reiter RJ: Melatonin reduces
the mortality of severely-infected COVID-19 patients. Melatonin
Res. 4:613–616. 2021.
|
|
182
|
Ren DL, Sun AA, Li YJ, Chen M, Ge SC and
Hu B: Exogenous melatonin inhibits neutrophil migration through
suppression of ERK activation. J Endocrinol. 227:49–60. 2015.
|
|
183
|
Maldonado MD, Mora-Santos M, Naji L,
Carrascosa-Salmoral MP, Naranjo MC and Calvo JR: Evidence of
melatonin synthesis and release by mast cells. Possible modulatory
role on inflammation. Pharmacol Res. 62:282–287. 2010.
|
|
184
|
Muxel SM, Pires-Lapa MA, Monteiro AWA,
Cecon E, Tamura EK, Floeter-Winter LM and Markus RP: NF-κB drives
the synthesis of melatonin in RAW 264.7 macrophages by inducing the
transcription of the arylalkylamine-N-acetyltransferase (AA-NAT)
gene. PLoS One. 7:e520102012.
|
|
185
|
Maldonado MD, García-Moreno H,
González-Yanes C and Calvo JR: Possible involvement of the
inhibition of NF-κB factor in anti-inflammatory actions that
melatonin exerts on mast cells. J Cell Biochem. 117:1926–1933.
2016.
|
|
186
|
Hasan MZ, Islam S, Matsumoto K and Kawai
T: Meta-analysis of single-cell RNA-seq data reveals phenotypic
switching of immune cells in severe COVID-19 patients. Comput Biol
Med. 137:1047922021.
|
|
187
|
Cardinali DP, Brown GM and Pandi-Perumal
SR: An urgent proposal for the immediate use of melatonin as an
adjuvant to anti-SARS-CoV-2 vaccination. Melatonin Res. 4:206–212.
2021.
|
|
188
|
Zipeto D, Palmeira JDF, Argañaraz GA and
Argañaraz ER: ACE2/ADAM17/TMPRSS2 interplay may be the main risk
factor for COVID-19. Front Immunol. 11:5767452020.
|
|
189
|
Shukla M, Htoo HH, Wintachai P, Hernandez
JF, Dubois C, Postina R, Xu H, Checler F, Smith DR, Govitrapong P
and Vincent B: Melatonin stimulates the nonamyloidogenic processing
of βAPP through the positive transcriptional regulation of ADAM10
and ADAM17. J Pineal Res. 58:151–165. 2015.
|
|
190
|
Zlacká J, Stebelová K, Zeman M and
Herichová I: Interactions of renin-angiotensin system and COVID-19:
The importance of daily rhythms in ACE2, ADAM17 and TMPRSS2
expression. Physiol Res. 70(S2): S177–S194. 2021.
|
|
191
|
Hazra S, Chaudhuri AG, Tiwary BK and
Chakrabarti N: Matrix metallopeptidase 9 as a host protein target
of chloroquine and melatonin for immunoregulation in COVID-19: A
network-based meta-analysis. Life Sci. 257:1180962020.
|
|
192
|
Cecon E, Izabelle C, Poder SL, Real F, Zhu
A, Tu L, Ghigna MR, Klonjkowski B, Bomsel M, Jockers R and Dam J:
Therapeutic potential of melatonin and melatonergic drugs on
K18-hACE2 mice infected with SARS-CoV-2. J Pineal Res.
72:e127722022.
|
|
193
|
Cecon E, Fernandois D, Renault N, Coelho
CFF, Wenzel J, Bedart C, Izabelle C, Gallet S, Le Poder S,
Klonjkowski B, et al: Melatonin drugs inhibit SARS-CoV-2 entry into
the brain and virus-induced damage of cerebral small vessels. Cell
Mol Life Sci. 79:3612022.
|
|
194
|
Loh D: The potential of melatonin in the
prevention and attenuation of oxidative hemolysis and myocardial
injury from cd147 SARS-CoV-2 spike protein receptor binding.
Melatonin Res. 3:380–416. 2020.
|
|
195
|
Morchang A, Malakar S, Poonudom K,
Noisakran S, Yenchitsomanus PT and Limjindaporn T: Melatonin
inhibits dengue virus infection via the sirtuin 1-mediated
interferon pathway. Viruses. 13:6592021.
|
|
196
|
Zhai X, Wang N, Jiao H, Zhang J, Li C, Ren
W, Reiter RJ and Su S: Melatonin and other indoles show antiviral
activities against swine coronaviruses in vitro at pharmacological
concentrations. J Pineal Res. 71:e127542021.
|
|
197
|
Tesarik J: Melatonin attenuates growth
factor receptor signaling required for SARS-CoV-2 replication.
Melatonin Res. 3:534–537. 2020.
|
|
198
|
Reiter RJ, Cardinali DP, Neel RL,
Rodriguez AD, Brown GM and Tesarik J: Rationale for the continued
use of melatonin to combat the delta variant of SARS-CoV-2.
Melatonin Res. 4:495–500. 2021.
|
|
199
|
Klann K, Bojkova D, Tascher G, Ciesek S,
Münch C and Cinatl J: Growth factor receptor signaling inhibition
prevents SARS-CoV-2 replication. Mol Cell. 80:164–174 e4. 2020.
|
|
200
|
Behl T, Kaur I, Aleya L, Sehgal A, Singh
S, Sharma N, Bhatia S, Al-Harrasi A and Bungau S: CD147-spike
protein interaction in COVID-19: Get the ball rolling with a novel
receptor and therapeutic target. Sci Total Environ.
808:1520722022.
|
|
201
|
Wang K, Chen W, Zhang Z, Deng Y, Lian JQ,
Du P, Wei D, Zhang Y, Sun XX, Gong L, et al: CD147-spike protein is
a novel route for SARS-CoV-2 infection to host cells. Signal
Transduct Target Ther. 5:2832020.
|
|
202
|
Mohamed Taha A, Adel Abdelkader Saed S,
Hossam-Eldin Moawad M, Abd El-Tawab Moawad W, Al-Hejazi T, Mousa Y,
Sharma R and Reiter RJ: Safety and efficacy of melatonin as an
adjuvant therapy in COVID-19 patients: Systematic review and
meta-analysis. Adv Med Sci. 68:341–352. 2023.
|
|
203
|
Hosseini A, Esmaeili Gouvarchin Ghaleh H,
Aghamollaei H, Fasihi Ramandi M, Alishiri G, Shahriary A,
Hassanpour K, Tat M and Farnoosh G: Evaluation of Th1 and Th2
mediated cellular and humoral immunity in patients with COVID-19
following the use of melatonin as an adjunctive treatment. Eur J
Pharmacol. 904:1741932021.
|
|
204
|
Alizadeh Z, Keyhanian N, Ghaderkhani S,
Dashti-Khavidaki S, Shokouhi Shoormasti R and Pourpak Z: A Pilot
study on controlling coronavirus disease 2019 (COVID-19)
inflammation using melatonin supplement. Iran J Allergy Asthma
Immunol. 20:494–499. 2021.
|
|
205
|
Darban M, Malek F, Memarian M, Gohari A,
Kiani A, Emadi A, Lavvaf S and Bagheri B: Efficacy of high dose
vitamin C, melatonin and zinc in iranian patients with acute
respiratory syndrome due to coronavirus infection: A pilot
randomized trial. J Cell Mol Anesth. 6:164–167. 2021.
|
|
206
|
Farnoosh G, Akbariqomi M, Badri T, Bagheri
M, Izadi M, Saeedi-Boroujeni A, Rezaie E, Ghaleh HEG, Aghamollaei
H, Fasihi-Ramandi M, et al: Efficacy of a low dose of melatonin as
an adjunctive therapy in hospitalized patients with COVID-19: A
randomized, double-blind clinical trial. Arch Med Res. 53:79–85.
2022.
|
|
207
|
Mousavi SA, Heydari K, Mehravaran H,
Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A and Shamshirian
A: Melatonin effects on sleep quality and outcomes of COVID-19
patients: An open-label, randomized, controlled trial. J Med Virol.
94:263–271. 2022.
|
|
208
|
Chavarría AP, Vázquez RRV, Cherit JGD,
Bello HH, Suastegui HC, Moreno-Castañeda L, Alanís Estrada G,
Hernández F, González-Marcos O, Saucedo-Orozco H, et al:
Antioxidants and pentoxifylline as coadjuvant measures to standard
therapy to improve prognosis of patients with pneumonia by
COVID-19. Comput Struct Biotechnol J. 19:1379–1390. 2021.
|
|
209
|
Esmaeili Gouvarchin Ghaleh H, Hosseini A,
Aghamollaei H, Fasihi-Ramandi M, Alishiri G, Saeedi-Boroujeni A,
Hassanpour K, Mahmoudian-Sani MR and Farnoosh G: NLRP3 inflammasome
activation and oxidative stress status in the mild and moderate
SARS-CoV-2 infected patients: Impact of melatonin as a medicinal
supplement. Z Naturforsch C J Biosci. 77:37–42. 2021.
|
|
210
|
Bologna C, Madonna P and Pone E: Efficacy
of prolonged-release melatonin 2 mg (PRM 2 mg) prescribed for
insomnia in hospitalized patients for COVID-19: A retrospective
observational study. J Clin Med. 10:58572021.
|
